FINGER LAKES REGIONAL EMS COUNCIL, INC.



TEMERGENCY MEDICAL SERVICES = in affiliation with Finger Lakes Community College

BLS Naloxone Administration

Agency Letter of Intent for Participation in the BLS Naloxone Program

We th	e members of	hereby request permission
to part	icipate in the Finger Lakes Regio	nal EMS Council BLS Naloxone Administration Program
We a	gree to abide by the followi	ng.
 3. 4. 6. 	All agency and personnel must Finger Lakes REMAC and New Our agency will provide and do testing for all active providers. Our agency agrees to participat which IN Naloxone are administ of the PCR must be sent to Fing If your agency, or one of your protocols, the privileges of provisuspended by the REMAC Any changes to the Required A business days.	cument annual BLS Naloxone updates with competency skill in the Regional Quality Improvement Program. All Calls in tered must be reviewed by the agency Medical Director. A copy or Lakes Program Agency within 24 hours. The ersonnel disregards these guidelines and/or other applicable iding pre-hospital Naloxone treatment may be revoked or gency Information will be reported to FLREMSC within 30
	gnatures below certify that the all aspects of participation in this re	ove conditions will be maintained and that we will be responsible gional program.
	Agency Officer	Agency Medical Director

FINGER LAKES REGIONAL EMS COUNCIL, INC.



TEMERGENCY MEDICAL SERVICES = in affiliation with Finger Lakes Community College

Medical Director Statement of Agreement

I hereby agree to serve as the Medical Director for:			
I understand that all patient care will be provided under my license, in accordance with NYS and Finger Lakes Regional EMS Council REMAC protocols and training guidelines, except in cases of gross negligence resulting injury or death.			
Upon Signing this document I agree to:			
Provide and/or assist with annual Naloxone in-service/updates and training			
Annually renew the Naloxone agreement with this agency			
Participate in QI, and review all calls in which Naloxone was administered and any other calls as necessary			
Provide medical leadership			
Act as a resource for continuing education			
Remain familiar with regional and NYS State BLS protocols			
If I have any questions concerning my responsibilities I will contact the Finger Lakes Regional EMS Council REMAC.			
MD Signature:			
MD Name printed:			
Date:			

BLS Naloxone Administration

Required Agency Information (Please Print Legibly)

Agency Name:	Phone Number:	
Address:	City:	Zipcode
1. Designated representative respo	onsible for the BLS Nalox	cone Administration Program:
Name:		
Daytime Phone:		
e-mail:		
2. Agency Officer In Charge:		
Name:		
Daytime Phone:	-	
e-mail:		
3. Agency Medical Director:		
Name:		
Daytime Phone:		
e-mail:		
4. Agency QI Coordinator: (Canno	ot be FLREMSC)	
Name: :		
Daytime Phone:	<u></u>	
•1		

BLS Naloxone Administration

5. V	We will receive Overdose Prevention Rescue Kits from:
6. N	Naloxone will be stored in the agency's station in the following manner:
7. I	Naloxone will be carried and secured on the ambulance(s) in the following manner:
8. 1	The following ALS agencies will be called for intercept:
Must be	completed by Non-transporting Agencies Only:
9. I	Primary transporting ambulance service:
1	Name:

BLS Naloxone Administration

Equipment List

The following minimum equipment should be carried on every BLS unit:

An Intranasal Naloxone Kit that contains the following:

- A. Two (2) naloxone hydrochloride pre-filled pre-filled Luer-Lock (Needless) Syringes conating 2mg/ml
- B. Two (2) mucosal atomization devices (MAD)
- C. One (1) container for security/storage

BLS Administration of Naloxone to Reverse Opiod Overdose Frequently Asked Questions

- 1. What us the reporting or follow-up process after we administer the medication? After you give a dose of the Naloxone please complete the BLS Naloxone QI Form and submit it to the Finger Lakes Regional EMS Council Program Agency office.
- 2. Is there CME credit available for this training program?

 CME credits will be awarded for completion of the regionally approved training that has been presented by one of the region's CICs

Naloxone (Narcan®)

Class

Synthetic Opiod antagonist

Description

Naloxone is a competitive narcotic antagonist used in the management and reversal of overdoses caused by narcotics and synthetic narcotic agents. Unlike other narcotic antagonists, which do not completely inhibit the analgesic properties of opiates, naloxone antagonizes all actions of morphine.

Onset and Duration

Onset:

Within 2 minutes

Duration:

30-60 minutes

Indications:

- 1. For the partial or complete reversal of CNS and respiratory depression induced by opiods:
 - a. Narcotic agonist:

Morphine sulfate

Heroin

Hydromorphone (Dilaudid)

Methadone

Meperidine (Demerol)

Paregoric

Fentanyl citrate (Sublimaze)

Oxycodone (Percodan)

Codeine

Propoxyphene (Darvon)

b. Narcotic agonist and antagonist

Butorphanol tartrate (Stadol)

Pentazocine (Talwin)

Nalbuphine (Nubain)

2. Decreased level of consciousness

Contraindications

Hypersensitivity

Use with caution in narcotic dependent patients who may experience withdrawal syndrome (including neonates of narcotic dependent mothers)

Adverse Reactions

Tachycardia Hypertension Hypotension Cardiac dysrhythmias Seizures

Nausea and vomiting

Diaphoresis

How Supplied

2mg/ml, prefilled syringe without needle Mucosal Atomizer Device (MAD) purchased separately

Protocol - CFR and EMT

M-2 Altered Mental Status with Suspected Narcotic Overdose

Special Considerations

Pregnancy Safety: Category B May not reverse hypotension

Caution should be exercised when administering Naloxone to narcotic addicts (may precipitate withdrawal with hypertension, tachycardia and violent behavior)